I'm finding this evolution incredibly interesting. About 6 or 7 years ago RVX was talking about increases in APO-A1 which was out of the "norm" at the time. A number of followers were suggesting that this little Cdn biotech was grasping at straws because they didn't hit the increase in HDL that they expected in the ASSERT trial so they were trying to justify their existence. Now it seems it's all coming around full circle. Increasing APO-A1 and reducing inflammation. Wouldn't it be nice, sweat justice actually if RVX blows the socks off with the results of this BETONMACE trial.

tada